DPPY (30, 60 mg/kg; i.g., once daily for 14 days) shows anti-IPF agents on the lung morphology and lung coefficient in mouse model[1].
DPPY (30, 60 mg/kg) significantly decreases the expression of IL-6, IL-17A, TNF-α and MDA in lung tissue in a dose dependent manner[1].
| Animal Model: | 5-6 week old, 20-25 g, C57BL mice (BLM-induced pulmonary inflammation and pulmonary fibrosis model)[1] |
| Dosage: | 30, 60 mg/kg |
| Administration: | I.g.; once daily for 14 days |
| Result: | Attenuated the pulmonary morphology changes and reduced the collagen disposition induced by BLM in mouse lung. |
